Novanta Inc.
NASDAQ•NOVT
執行長: Mr. Matthijs Glastra
板塊: Technology
行業: Hardware, Equipment & Parts
上市日期: 1999-03-24
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
聯絡資訊
市值
$4.51B
本益比 (TTM)
91.5
23.5
股息率
--
52周最高
$149.95
52周最低
$98.27
52周範圍
排名40Top 42.0%
4.1
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
一般 • 4.1 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q4 2025 數據
營業收入
$258.35M+0.00%
近4季度走勢
每股收益
$0.46+0.00%
近4季度走勢
自由現金流
$5.13M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Revenue Growth Strong Total revenue reached $980.6M, marking a 3.3% increase; Medical Solutions revenue grew 4.6% to $479.8M.
Major Equity Financing Closed Issued 6.50% tangible equity units, securing $613.1M net proceeds in November 2025 to bolster liquidity position.
Backlog Signals Future Demand Consolidated backlog increased to $481.2M as of year-end 2025, up from $445.5M in 2024, indicating order strength.
Automation Revenue Rises Automation Enabling Technologies segment revenue increased 2.1% to $500.8M, driven by robotics and automation product sales.
關注風險
Operating Income Declined Operating income fell 15.0% to $94.0M in 2025, driven by higher SG&A and restructuring/acquisition related costs.
Customer Concentration Exposure Top two OEM customers represented 23% of 2025 consolidated revenue, posing concentration risk if orders significantly reduce.
Regulatory Complexity High Subject to extensive and dynamic medical device regulations across US, EU, and UK, increasing compliance complexity and costs.
Margin Pressure Evident Automation segment gross margin slightly decreased due to higher tariff costs and temporary increases from regional manufacturing strategy.
未來展望
Medical Sales Mix Focus Strategy centers on improving business mix to increase medical sales percentage of total revenue via new product introductions.
Capital Structure Management Debt level stands at $259.6M total; $850.0M unused borrowing capacity available under the revolving credit facility.
Operational Efficiency Improvement Plans include strengthening operational performance via lean manufacturing and advancing strategic sourcing initiatives across major sites.
Technology Acquisition Strategy Will continue broadening portfolio through investment in new product development and pursuing complementary medical technology acquisitions.
同行對比
營業收入 (TTM)
$4.13B
$3.71B
$3.08B
毛利率 (最新季度)
102.1%
65.5%
58.7%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| VICR | $8.75B | 72.5 | 18.7% | 1.6% |
| ESE | $7.97B | 27.1 | 21.3% | 7.9% |
| DOCN | $7.96B | 25.9 | -214.1% | 39.8% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
3.4%
溫和增長
4季度淨利複合增長率
-6.3%
盈利能力下滑
現金流穩定性
100%
現金流表現優異
深度研究
下次財報:2026年5月4日
每股收益:-
|營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料